Hans Tesch

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Multiple Myeloma

Clinical Practice

Clinical Decision Support

Epidermal Growth Factor Receptor

Top Venues

Future oncology (London, England)

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, Andreas Hartkopf, Wilhelm Bloch, Thomas Decker, Christoph Uleer, Oliver Stötzer, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Thomas Fischer, Julia Kreuzeder, Gernot Guderian, Peter A Fasching
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. International journal of cancer 155 (1) (2024)
Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, Andreas Hartkopf, Wilhelm Bloch, Thomas Decker, Christoph Uleer, Oliver Stötzer, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Thomas Fischer, Julia Kreuzeder, Gernot Guderian, Peter A Fasching
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. International journal of cancer 155 (1) (2024)
Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, Andreas Hartkopf, Wilhelm Bloch, Thomas Decker, Christoph Uleer, Oliver Stötzer, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Thomas Fischer, Julia Kreuzeder, Gernot Guderian, Peter A Fasching
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. International journal of cancer (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Hans Tesch, Oliver Stoetzer, Thomas Decker, Christian M Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter Andreas Fasching, Michael P Lux, Diana Lüftner, Peyman Hadji, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Florin-Andrei Taran
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. International journal of cancer 144 (4) (2018)